What do systematic reviews say?

Exercise vs pharmacological treatments

• Exercise for depression 2013 · Cochrane Headline outcomes only
  no estimate extracted
  0 studies · 1 participants
  Moderate

Augmentation of current antidepressant (fluoxetine 20 mg/d) with mianserin (60 mg/d) vs placebo plus antidepressant

The review found no eligible studies for this question.

• Pharmacological interventions for treatment‐resistant depression in adults 2019 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Augmentation of current antidepressant (SSRI) with busiprone (20 mg/d to 60 mg/d) vs placebo plus antidepressant

The review found no eligible studies for this question.

• Pharmacological interventions for treatment‐resistant depression in adults 2019 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Augmentation of current antidepressant (various) with cariprazine (1 mg/d to 4.5 mg/d) vs augmentation of current antidepressant (various) with placebo

The review found no eligible studies for this question.

• Pharmacological interventions for treatment‐resistant depression in adults 2019 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Augmentation of current antidepressant (fluoxetine 20 mg/d to 60 mg/d) with olanzapine (5 mg/d to 20 mg/d) vs augmentation of current antidepressant (fluoxetine 20 mg/d to 60 mg/d) with placebo

The review found no eligible studies for this question.

• Pharmacological interventions for treatment‐resistant depression in adults 2019 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Augmentation of current antidepressant (SSRI) with ziprasidone (40 mg/d to 160 mg/d) vs augmentation of current antidepressant (SSRI) with placebo or continue on SSRI monotherapy

The review found no eligible studies for this question.

• Pharmacological interventions for treatment‐resistant depression in adults 2019 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Switching to mianserin (60 mg/d) vs continuing on current antidepressant (fluoxetine 20 mg/d)

The review found no eligible studies for this question.

• Pharmacological interventions for treatment‐resistant depression in adults 2019 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Psychological therapy vs enhanced or structured care

• Non‐pharmacological interventions for somatoform disorders and medically unexplained physical symptoms (MUPS) in adults 2014 · Cochrane Headline outcomes only
  no estimate extracted
  4 studies · 497 participants
  Moderate

Psychological therapy vs Waitlist/Usual Care

• Non‐pharmacological interventions for somatoform disorders and medically unexplained physical symptoms (MUPS) in adults 2014 · Cochrane Headline outcomes only
  no estimate extracted
  7 studies · 730 participants
  Low

Natural products vs placebo

The review found no eligible studies for this question.

• Pharmacological interventions for somatoform disorders in adults 2014 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Augmentation of current antidepressant (SSRI/SNRI) with mirtazapine (30 mg/d) vs augmentation of current antidepressant (various) with placebo

• Pharmacological interventions for treatment‐resistant depression in adults 2019 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 447 participants
  High

Tricyclic antidepressants vs placebo

The review found no eligible studies for this question.

• Pharmacological interventions for somatoform disorders in adults 2014 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

New‐generation antidepressants vs placebo

• Pharmacological interventions for somatoform disorders in adults 2014 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 163 participants
  Very low

Antipsychotics vs placebo

The review found no eligible studies for this question.

• Pharmacological treatment for psychotic depression 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Antidepressants vs antidepressants

The review found no eligible studies for this question.

• Pharmacological treatment for psychotic depression 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Antidepressants vs antipsychotics

The review found no eligible studies for this question.

• Pharmacological treatment for psychotic depression 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Antidepressant plus antipsychotic vs placebo

The review found no eligible studies for this question.

• Pharmacological treatment for psychotic depression 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Antidepressant plus antipsychotic vs placebo/no adjunctive treatment + antipsychotics

The review found no eligible studies for this question.

• Pharmacological treatment for psychotic depression 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Antidepressant plus antipsychotic vs placebo plus antidepressant

The review found no eligible studies for this question.

• Pharmacological treatment for psychotic depression 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found
• Pharmacological treatment for psychotic depression 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Antidepressants vs placebo

The review found no eligible studies for this question.

• Pharmacological treatment for psychotic depression 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found